Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease; progressive multiple sclerosis (PMS); Alzheimer’s disease (AD); and other neurodegenerative diseases. Its NurOwn, a cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived MSCs to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. It has completed a Phase III pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells. The Company's wholly owned subsidiary, Brainstorm Cell Therapeutics Ltd. holds exclusive rights to commercialize NurOwn technology.
Back to dashboard
Company Information
About this company
Key people
Peter J. Pitts
Executive Chairman of the Board, Chief Strategic Regulatory Officer
Anthony John Polverino
Independent Director
Chaim Lebovits
President, Chief Executive Officer
Irit Arbel
Independent Vice Chairman of the Board
Alla Patlis
Interim Chief Financial Officer, Controller
Hartoun Hartounian
Executive Vice President, Chief Operating Officer
Uri Yablonka
Director, Executive Vice President, Chief Business Officer, Secretary
Stacy R. Lindborg
Director
Menghisteab Bairu
Independent Director
Nir Naor
Independent Director
Click to see more
Key facts
- Shares in issue11.03m
- EPICBCLI
- ISINUS10501E3009
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$11.92m
- Employees20
- ExchangeOver The Counter
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.